Latest Conference Articles

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

ACG represents the first major in-person conference since the COVID-19 pandemic.

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

The rates of adverse events was similar across all 4 indications in comparison to the placebo group.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.